Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125074642 | 12507464 | 2 | F | 20160614 | 20160801 | 20160629 | 20160805 | PER | PHEH2016US015875 | NOVARTIS | 83.24 | YR | M | Y | 0.00000 | 20160805 | PH | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125074642 | 12507464 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 9.5 MG, UNK | 4446B | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | ||||||
| 125074642 | 12507464 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG, QD | 4345A | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125074642 | 12507464 | 1 | Memory impairment |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125074642 | 12507464 | Product adhesion issue | |
| 125074642 | 12507464 | Underdose |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125074642 | 12507464 | 1 | 20160411 | 20160411 | 0 |